🔹 EPS: $0.63 (Est. $0.48) 🟢
🔹 Revenue: $17.8B (Est. $17.28B) 🟢; UP +22% YoY
🔸 Pfizer anticipates $4.5B in cost savings by 2025.
FY25 Guidance:
🔹 EPS: $2.80-$3.00 (Est. $2.93) 🟡
🔹 Revenue: $61B-$64B (Est. $63B) 🟡
🔹 Adjusted SI&A Expenses: $13.3B-$14.3B
🔹 Adjusted R&D Expenses: $10.7B-$11.7B
🔹 Effective Tax Rate: ~15%
Segment Performance:
🔹 Biopharma Revenue: $17.41B (UP +23% YoY)
🔹 Pfizer CentreOne (PC1): $325M (DOWN -11% YoY)
🔹 Pfizer Ignite: $26M (UP +30% YoY)
Key Drug & Product Highlights:
🔹 Comirnaty (COVID-19 Vaccine): $3.4B (DOWN -38% YoY)
🔹 Paxlovid: $727M (UP +3.9B YoY, vs. -$3.1B prior Q4 due to one-time reversal)
🔹 Legacy Seagen Portfolio: $915M (Prev. $132M in Q4’23)
🔹 Vyndaqel Family: UP +60% YoY
🔹 Eliquis: UP +13% YoY
🔹 Xtandi: UP +24% YoY
🔹 Nurtec ODT/Vydura: UP +39% YoY
Declining Products:
🔹 Abrysvo: DOWN -62% YoY (Decline in U.S. vaccinations)
🔹 Xeljanz: DOWN -29% YoY (Due to label changes & exclusivity loss in Canada)
🔹 Oncology Biosimilars: DOWN -35% YoY (Supply constraints & price declines)
Operational Cost & Expense Metrics (Q4 2024):
🔹 Cost of Sales: $5.91B (Prev. $7.56B); DOWN -22% YoY
🔹 SI&A Expenses: $4.27B (Prev. $4.57B); DOWN -7% YoY
🔹 R&D Expenses: $3.04B (Prev. $2.82B); UP +8% YoY
🔹 Effective Tax Rate: 19.2%
Capital Allocation & Shareholder Returns:
🔹 Total R&D Investments: $10.8B
🔹 Dividends Paid: $9.5B ($1.68 per share)
🔹 No Share Repurchases in 2024
🔹 Remaining Share Buyback Authorization: $3.3B (No repurchases expected in 2025)
Strategic Developments & Pipeline Updates:
🔸 Braftovi Combo (Colorectal Cancer): Positive Phase 3 results, showing significant survival benefits.
🔸 Hympavzi (Hemophilia A treatment): Received European Commission approval.
🔸 Ibrance (Breast Cancer): Phase 3 data shows improved progression-free survival.
